HIV Vaccine Studies
In the United States HIV disproportionately affects certain groups and populations; however, HIV can affect anyone. Worldwide there are currently over 40 million people living with HIV. That number is growing.
The Vanderbilt HIV Vaccine Program is looking for healthy adults (ages 18-55) from all walks of life who are not living with HIV to participate in an HIV prevention study.
You cannot get HIV from participating in the study.
Volunteers must be available locally for approximately 12 months. Volunteers will be compensated.
You can help fight the HIV/AIDS epidemic
Call 615-936-7327 or email vic.sorrell@vumc.org for more information.
In order to develop HIV prevention methods that will work for everyone, we need help from everyone!
ALL RACIAL AND ETHNIC GROUPS ARE ENCOURAGED TO CONTACT OUR PROGRAM.
Current Studies
HVTN 141: is a phase 1 clinical trial to evaluate the safety, pharmacokinetics, and in vitro neutralization of ePGT121v1-LS, VRC07-523LS, and PGDM1400LS administered in multiple doses, and routes to adult participants without HIV-1.
HVTN 144: is a Phase 1/2 clinical trial evaluating the safety and immunogenicity of an HIV-1 vaccine regimen using adenovirus vectors. The study assesses the ability of the vaccine to induce strong antibody and T-cell responses, with the goal of offering broad protection against multiple HIV-1 subtypes.
HVTN 307: is a Phase 1 clinical trial evaluating the safety and immunogenicity of a novel HIV-1 vaccine regimen using lipid nanoparticle-encapsulated mRNA technology. The study aims to assess the vaccine’s ability to elicit broad and potent antibody and T-cell responses to prevent HIV-1 infection across diverse viral strains.
HVTN 319: is a Phase 1 clinical trial designed to evaluate the safety, tolerability, and immunogenicity of an HIV-1 vaccine regimen based on mosaic and trimeric antigens. The trial aims to determine the vaccine’s ability to elicit broad, cross-clade antibody and T-cell responses to protect against diverse HIV-1 strains.
Upcoming Studies
HVTN 324: is a phase 1 clinical trial to evaluate the safety and immunogenicity of ACU-026-001-1–adjuvanted CH505 protein nanoparticles (DV901-NP) alone or boosted with CH505 NP (DV902-NP) or CH505 mRNAs in adults in overall good health without HIV. (Projected to open in Q3 of 2026.)